SMARCB1 and rhabdoid tumor: Importantly, these pathways have been linked to aberrant SMARCB1‐deficient SWI/SNF activity in rhabdoid tumor (Chakravadhanula et al, 2015; Johann et al, 2016; Torchia et al, 2016).